Welcome to our dedicated page for Synergy Chc SEC filings (Ticker: SNYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Synergy CHC Corp. (NASDAQ: SNYR) SEC filings page brings together the company’s official disclosures as a smaller reporting company in the consumer health and wellness sector. Synergy develops and markets branded products such as FOCUSfactor® brain-health supplements and functional beverages and Flat Tummy® women’s wellness offerings, and its regulatory filings provide detailed insight into how this business is structured and financed.
Through annual reports on Form 10‑K and quarterly reports on Form 10‑Q, Synergy reports product sales, license revenue, gross profit, operating expenses, operating income, net income, and non‑GAAP measures like EBITDA and Adjusted EBITDA. These filings also describe working capital, inventory levels, debt obligations, and stockholders’ equity or deficit, giving investors a view of how the company funds expansion of its FOCUSfactor® and Flat Tummy® brands.
Current reports on Form 8‑K document material events such as quarterly earnings releases, public offerings of common stock, changes to equity incentive plans, authorization of preferred stock, and board or executive changes. For example, Synergy has used Form 8‑K to report an underwritten public offering of common stock, amendments to its 2024 Equity Incentive Plan, authorization of preferred stock, and governance updates including director appointments and role transitions.
Registration statements such as the Form S‑1 provide additional background on the company’s business, risk factors, use of proceeds, capital structure, and status as a smaller reporting company. Investors interested in ownership changes and executive incentives can review equity plan amendments and related disclosures within these filings. On this page, AI-powered tools can help summarize lengthy documents, highlight key financial and governance changes, and make complex sections of 10‑K, 10‑Q, 8‑K, and S‑1 filings easier to understand.
Use this filings hub to track Synergy CHC Corp.’s official financial reporting, capital raises, governance actions, and other regulatory disclosures that shape the outlook for SNYR stock.
Synergy CHC Corp. amended its term loan, changing repayment timing, interest mechanics, pricing, covenants and default terms, and issued a new lender warrant. The amended agreement schedules principal payments of $175,000 on each of July 1, 2026 and October 1, 2026, then $525,000 on January 1, 2027 and $350,000 quarterly from April 1, 2027. If the company does not raise at least $10,000,000 of equity by September 30, 2026, the loan margin increases by 2.00% per year until that target is met. Interest due on March 2, 2026 must be paid in kind, and the company can elect to pay all or part of the April 1, 2026 interest in kind. New financial tests include minimum Consolidated Adjusted EBITDA of $500,000 for the quarter ended June 30, 2026 and $1,000,000 for the quarter ended September 30, 2026, plus revised senior net leverage thresholds, initially up to 20.00:1.00 for the quarter ended December 31, 2025. Equity issuance proceeds must follow a new waterfall where the first $6,000,000 can be retained and the next $4,000,000 must repay the term loan, with additional prepayments on amounts above $10,000,000 depending on leverage. The amendment also temporarily forces loans onto a reference rate and restricts future Term SOFR elections until at least $4,000,000 of principal has been repaid. In connection with the amendment, the company issued a 10‑year warrant giving a lender the right to buy 3,000,000 common shares at $0.00001 per share, exercisable only after a defined event of default and capped at 19.9% ownership unless stockholders approve a higher level by June 30, 2026.
Synergy CHC Corp. reported that on February 27, 2026, Gravity Pharma General Trading LLC terminated, ab initio, a Brand License Agreement originally signed on March 31, 2025 and later amended on June 30, 2025. The agreement had granted Gravity an exclusive license to sell and market certain FOCUSfactor and Flat Tummy Co. products in the United Arab Emirates and Turkey in exchange for an aggregate license fee of $2.9 million, which the company had previously recorded as revenue. Despite the termination, Synergy CHC states that it continues to pursue registration and marketing of these products in the same territories.
Synergy CHC Corp. has filed a shelf registration statement that allows it to offer and sell up to $100 million of securities, including common stock, preferred stock, warrants, debt securities, subscription rights and units, in one or more future offerings. The filing also contemplates a sales agreement prospectus for common stock, with up to $5.69 million of shares available under that program inside the overall $100 million limit.
Synergy’s common stock trades on the Nasdaq Capital Market under the symbol SNYR; the last reported price on November 20, 2025 was $2.08 per share. As of that date, 11,251,853 shares of common stock were outstanding. The company plans to use any net proceeds for research and development, working capital, general corporate purposes, potential acquisitions and reducing indebtedness.
Synergy is a consumer health care, beauty and lifestyle products company built around two core brands, FOCUSfactor and Flat Tummy, sold through major retailers and online. Net revenue was $34.8 million for 2024, down 19% from 2023, and $24.3 million for the nine months ended September 30, 2025, down 1% year over year, with a new $2.9 million license agreement contributing to 2025 revenue.
Synergy CHC Corp. reported Q3 2025 results. Revenue was $8,010,112 versus $7,126,333 a year ago as shipments normalized after 2024 packaging changes. Gross profit rose to $5,680,816 with a 71% margin (from 67%). Net income was $125,327 compared to $783,593 in Q3 2024, reflecting higher operating and interest costs.
For the first nine months of 2025, revenue was $24,315,642 (vs. $24,563,036), and net income increased to $2,474,827 (vs. $2,019,309). Cash was $1,006,489 and total assets $20.69M at September 30, 2025. Total liabilities were $28.94M, and stockholders’ deficit improved to $(8.25)M.
The company refinanced with a $17.5M term loan at Term SOFR + 8.5% maturing in 2029, repaid legacy debts (including $10.0M to a shareholder-lender) and recorded debt settlement gains. In August 2025, it completed an IPO, issuing 1,750,000 shares for net proceeds of $3,880,462. Shares outstanding were 11,251,853 as of November 12, 2025.
Synergy CHC Corp. furnished an 8-K to announce it issued a press release with financial and operating results for the quarter ended September 30, 2025. The company attached the press release as Exhibit 99.1, dated November 13, 2025, and noted the information is furnished, not filed, under the Exchange Act.
Alfred Baumeler, who serves as President and a Director of Synergy CHC Corp. (SNYR), reported a stock option grant on 09/18/2025. The grant is for 150,000 options to purchase common stock at an exercise price of $2.38 per share. The filing lists 150,000 shares beneficially owned following the transaction and records ownership as direct. The option has an expiration date shown as 09/18/2030. The grant vests one-third on the first anniversary of the grant date and the remaining two-thirds vest in equal monthly installments over the following 24 months, subject to continued service.
Jaime Fickett, identified as Chief Financial Officer of Synergy CHC Corp. (SNYR), reported a grant of a stock option on 09/18/2025. The option covers 150,000 shares of common stock with an exercise price of $2.38 per share and an expiration date shown as 09/18/2030. The filing states the full award is held directly by the reporting person following the transaction. The option vests one-third on the first anniversary of the grant and the remaining two-thirds in equal monthly installments over the subsequent 24 months, subject to continued service. The form was signed by an attorney-in-fact on 09/22/2025.
Synergy CHC Corp. (SNYR) reported a Form 4 showing a stock option grant to Kenek Brands Inc., which is controlled by reporting person Jack Ross, the company's CEO and Chairman. The derivative award is a 750,000-share option with an exercise price of $2.38, recorded on 09/18/2025. The filing states the option vests one-third on the first anniversary of grant and the remaining two-thirds in equal monthly installments over the following 24 months, subject to continued service. The reporting person disclaims direct ownership; the shares are owned directly by Kenek Brands Inc., making Ross an indirect beneficial owner. The Form is signed by counsel on 09/22/2025.
Synergy CHC Corp. reported that on September 22, 2025, board member Scott Woodburn resigned from the Board of Directors and all its committees in connection with his new role as the Company’s Head of Strategic Partnerships. The company states that his resignation was not due to any disagreement with the company, its board, or management regarding operations, policies, or practices.
The Board appointed Teresa Thompson to fill the resulting board vacancy and to serve on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. She will receive annual cash compensation of $25,000 and an annual equity award of $25,000 for her board service. Thompson previously served as a pharmacy OTC buyer for Costco Wholesale from September 1986 to June 2025, overseeing U.S. vitamins and supplements, and was appointed for her experience in the vitamin, supplement, and retail markets.
Synergy CHC Corp. entered a material underwriting agreement and sold 1,750,000 shares of common stock at $2.50 per share in a public offering, generating gross proceeds of $4.375 million before fees and expenses. Bancroft Capital, LLC acted as representative of the underwriters, who also received a 45-day option to purchase up to 262,500 additional shares to cover over-allotments at the same public price, less underwriting discounts and commissions.
The company plans to use the net proceeds for working capital and other general corporate purposes. It also issued Representative Warrants to Bancroft Capital, LLC and its designees to purchase up to 52,500 shares at an exercise price of $2.75 per share, subject to a 180-day lock-up and 180-day non-exercise period from the pricing date, with expirations staggered over the third, fourth, and fifth anniversaries of the closing date.